Lung Cancer
Conditions
Keywords
Lung Cancer, Stereotactic radiotherapy, Image guidance, breathing adaption, tumor motion, implanted marker
Brief summary
The purpose of this study is to quantify the variation in tumour middle position during a course of stereotactic body radiotherapy (SBRT), and thereby be able to design radiotherapy margins that takes into account the full motion span throughout an entire course of SBRT.
Detailed description
Lung tumours move with respiration. This must be considered when designing margins for radiotherapy. This movement can be quantified by fluoroscopy or 4DCT. It is possible to identify a tumour middle position for planning. This middle position will vary from day to day and the extent of this variation is not fully known. The aim of this study is to quantify the variation in tumour middle position during a course of stereotactic body radiotherapy (SBRT), and thereby be able to design margins for patients that take into account the full motion span throughout an entire course of SBRT Patients: 15 consecutive patients with inoperable low stage lung cancer or solitary metastases to the lung (1-2) referred for SBRT - 45 Gy/3 fractions. Methods: A gold coil will be implanted into the lung tumour one week before the planning. At planning and all treatment days supplementary 4DCT of thorax and two orthogonal fluoroscopy sessions will be performed. Tumour motion in the superior-inferior, medio-lateral and cranio-caudal direction will be measured and variation in amplitude and baseline for the tumour motion will be reported. Perspective: By examining the variation in tumour movement it will be possible design margins for SBRT, accounting for the full tumour motion span and minimizing the risk of geographical miss and thereby optimizing the chance for local tumour control.
Interventions
CT - guided implantation into lung tumors
Sponsors
Study design
Eligibility
Inclusion criteria
* tumor \> 6 cm * no more than 2 tumours * histological proven non small celled lung cancer * signed Informed Consent
Exclusion criteria
* Serious bleeding disorder * Performance status 3-4 * Tumour close to large vessels (judged by interventional radiologist)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| motion of lung tumours | 3 weeks | measured on 4DCT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| toxicity of implanting gold coils into lung tumours | 1 year | complication rate |
Countries
Denmark